Supplementary_Tables.docx (30.24 kB)

Supplementary Tables. Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations..docx

dataset

posted on 2020-11-30, 00:26 authored by Karen L. Reckamp, Jasmine A. McQuerry, Isa Mambetsariev, Rebecca Pharaon, Susan E. Yost, Jeremy Fricke, Tamara Mirzapoiazova, Raju K. Pillai, Ziad Khan, Marwan Fakih, Yuan Yuan, Marianna Koczywas, Erminia Massarelli, Prakash Kulkarni, Sumanta K. Pal, Martin Sattler, Andrea Bild, Ravi Salgia

Supplementary Tables. Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations.

Background

The implication of MET alterations in solid tumors and the immune microenvironment remains elusive.

Materials & Methods

FFPE samples of 21 patients with solid tumors harboring MET alterations were used for IHC staining. Extracted RNA was analyzed with the NanoString nCounter human PanCancer Immune Profiling Panel.

Results

Patients were diagnosed with lung (N=10), breast (N=5), genitourinary (N=3), or colorectal cancer (N=3). Eleven had a MET missense mutation, 4 had an exon 14 splice site mutation, and 6 had MET amplification. CD6, CCL19, ATM, CD40LG, XCR1, MAGEA1, ATM and CCL19 genes were significantly differentially expressed in MET-altered cancers.

Conclusion

MET alterations may have a role in various solid tumors as potential therapeutic targets and combination therapy candidates with immune checkpoint inhibitors.